Future symptomatic therapy in Parkinson’s disease

Ruth Djaldetti, Shlomit Yust-Katz, Eldad Melamed

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


The treatment of Parkinson’s disease (PD) is continuously evolving. The last three decades have witnessed an explosion of new drugs with different mechanisms of action for alleviating not only the motor symptoms of PD, but also the autonomic, psychiatric, and cognitive symptoms that adversely affect daily living. Treatment trends have shifted from surgery (before the revolutionary discovery of levodopa) to medical treatment and back to surgery (with the advances in stereotactic procedures and transplantation and disappointment with the poorly manageable side effects of levodopa). The current medical therapy for the motor symptoms of the disease includes levodopa preparations, dopamine agonists, and dopamine extenders such as monoamine oxidase B (MAO-B) inhibitors and catechol-O-methyl transferase (COMT) inhibitors. Anticholinergic, serotonergic, noradrenergic, and GABAergic medications are used to treat the secondary long-term dopaminergic symptoms and the nonmotor symptoms (Table 81.1). The future holds much promise for patients with PD. This chapter envisions what the next decades may look like in terms of the symptomatic medical treatment of PD.

Original languageEnglish
Title of host publicationParkinson's Disease, Second Edition
PublisherCRC Press
Number of pages13
ISBN (Electronic)9781439807156
ISBN (Print)9781439807149
StatePublished - 1 Jan 2012


Dive into the research topics of 'Future symptomatic therapy in Parkinson’s disease'. Together they form a unique fingerprint.

Cite this